Overview

CKD-396 Drug-drug Interaction Study(B) (CKD-396 DDI(B) P1)

Status:
Completed
Trial end date:
2016-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate a pharmacokinetic drug interaction between sitagliptin and lobeglitazone in healthy male volunteers.
Phase:
Phase 1
Details
Lead Sponsor:
Chong Kun Dang Pharmaceutical
Treatments:
Sitagliptin Phosphate